Compare Quest Diagnostics Inc (DGX) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Morgan Stanley — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Morgan Stanley trades at $229.1 (market cap $359.10B). The key difference: Morgan Stanley is far larger — about 15.8× Quest Diagnostics Inc's market cap, and Morgan Stanley pays the higher dividend (1.76%). Which is the better fit depends on your goals.
| DGX | MS | |
|---|---|---|
Market Cap | $22.80B | $359.10B |
Sector | Health | Financials |
52-Week High | $216.02 | $228.17 |
52-Week Low | $166.42 | $139.09 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Morgan Stanley (MS) trades at $221.09, down 0.54% on the day, with a bullish technical signal from moving averages and strong fundamental performance including three consecutive quarterly earnings beats. Revenue grew to $66.0B in 2025 with net income margin expanding to 25.56%, while analyst consensus remains positive with a $225.80 price target. Recent news highlights the firm's role in leading Anthropic's upcoming IPO and expanding AI integration in wealth management.
The outlook for MS is favorable given earnings momentum and strategic positioning in high-growth areas like AI and IPO advisory, though risks include volatile cash flows and high debt levels. The stock presents a potential 2.1% upside to the consensus target, supported by 53.85% analyst buy ratings, but investors should monitor interest expense and macroeconomic impacts on financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
